Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
Key Highlights
- ➤Adlai Nortye (ANL) appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
- ➤Christopher Liu brings nearly a decade of biotechnology and oncology equity research experience
- ➤Liu most recently served as Managing Director of equity research at Lucid Capital Markets
Expert Statements
Carsten Lu, Chairman and Chief Executive Officer of Adlai Nortye
“We are pleased to welcome Chris to Adlai Nortye. His deep understanding of oncology and extensive experience in the healthcare capital markets will be valuable as we continue to strengthen our engagement with the global investment community, enhance our external communications, and advance our pipeline.”
Christopher Liu, Head of Investor Relations and Public Relations at Adlai Nortye
“I am excited to join Adlai Nortye at this important stage of the Company’s development. I look forward to working with the team to deepen engagement with investors and other key stakeholders, and to effectively communicate the Company’s strategy, progress, and long-term value.”
SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology.
“We are pleased to welcome Chris to Adlai Nortye,” said Carsten Lu, Chairman and Chief Executive Officer of Adlai Nortye. “His deep understanding of oncology and extensive experience in the healthcare capital markets will be valuable as we continue to strengthen our engagement with the global investment community, enhance our external communications, and advance our pipeline.”
Get started
Create a free account to read the full story.